Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$70.37 USD

70.37
1,742,354

+0.14 (0.20%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $70.37 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Here's Why You Should Retain AmerisourceBergen (ABC) Stock Now

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.

Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How

Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.

Masimo (MASI) Ties Up to Educate on Prescription Opioid Overuse

Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.

QIAGEN (QGEN) to Join DAX Riding on Molecular Diagnostics Feat

QIAGEN (QGEN) is experiencing significant improvements in non-COVID areas of its molecular diagnostics portfolio.

Quidel's (QDEL) QuickVue OTC COVID-19 Test Now Widely Available

In-store and online availability of Quidel's (QDEL) QuickVue OTC COVID-19 Test is expected to meet the rising COVID-19 testing needs across the United States.

Why Is Henry Schein (HSIC) Down 0.8% Since Last Earnings Report?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Boston Scientific (BSX) New Buyout to Aid Kidney Stone Line

Boston Scientific (BSX) shares a 20-year long relationship with Lumenis and already offers the Lumenis urology laser portfolio in the United States and Japan through a distribution arrangement.

Here's Why You Should Retain Stryker (SYK) Stock Right Now

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure raises a concern.

Orthofix (OFIX) Fitbone Used in 1st US Pediatric Patient Implant

Orthofix's (OFIX) Fitbone system is the only intramedullary limb lengthening solution to get FDA clearance for pediatric and adult use.

Abbott's (ABT) Heart Failure Device Study Outcome Favorable (Revised)

Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.

Veeva (VEEV) MedTech Suite to Aid B. Braun Speed Up Trials

Adoption of Veeva's (VEEV) unified suites of cloud applications is likely to provide a significant boost to the company's Veeva Development Cloud business.

NextGen's (NXGN) Solutions to Boost Care for Homeless Community

NextGen's (NXXGN) solutions collaborate with Neighborhood Health to provide care to Nashville's homeless community through the latter's street medicine program.

Walgreens (WBA) to Stock LUCEMYRA Across US With New Pact

Walgreens' (WBA) agreement with US WorldMeds finalized as recent report outlines a surge of 30% in drug overdose deaths in 2020.

BD's (BDX) Latest Diagnostic System to Improve Lab Efficiency

BD's (BDX) new system is expected to address labs' needs for high-volume processing and increases in efficiency.

Here's Why You Should Retain McKesson (MCK) Stock Right Now

McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.

Masimo (MASI) Strengthens Global Footprint With New Launch

Masimo's (MASI) western Europe launch of SafetyNet Alert not only expands its global presence but also aids in protecting patients taking opioids at home.

Hill-Rom (HRC) Hits a New 52-Week High: What's Driving It?

Investors are optimistic about Hill-Rom (HRC) on impressive third-quarter fiscal 2021 performance and raised 2021 guidance.

Labcorp (LH) Base Business Grows Amid a Tough Volume Scenario

LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.

Abbott's (ABT) Heart Failure Device Study Outcome Favorable

Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.

Reasons to Hold on to Veeva Systems (VEEV) Stock For Now

Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.

Medtronic's (MDT) Micra TPS CED Study Outcome Favorable

Medtronic's (MDT) Micra TPS new study data supports the relationship of a lower risk of complications with leadless pacing.

Here's Why You Should Hold on to LabCorp (LH) Stock Now

Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.

Phibro (PAHC) Q4 Earnings Match Estimates, Margins Down

Phibro (PAHC) sees revenue growth in fourth-quarter fiscal 2021 due to strength in all three segments.

Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges

According to Illumina (ILMN), GRAIL will continue to operate as a separate company until the ongoing regulatory review by the EC is completed.